MedPath

Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight

Not Applicable
Completed
Conditions
Overweight
Obesity
Registration Number
NCT00502658
Lead Sponsor
Pharmanex
Brief Summary

Excessive body weight is becoming a concern around the world, for example over half of the American adult population is overweight or obese. The purpose of this study is to determine whether dietary supplements and shakes containing a combination of nutrients/ingredients individually shown in research studies to reduce hunger, enhance metabolism, reduce the body's ability to 'store' fat, and enhance energy, promote healthy body weight and composition over 12 weeks. A further study objective is to determine whether the inclusion of a personal, easy to use, energy tracking device for the measurement of daily energy intake and expenditure also helps with the promotion of healthy body weight and body composition.

In this prospective, blinded study 120 volunteers who meet the entrance criteria including a BMI 25-35 kg/m2 and sign the informed consent form to participate in a 12 week long study will be recruited. All subjects will consume a multi-vitamin, mineral and fish oil supplement. Subjects will be randomly assigned to a control or experimental group and stratified by BMI 25-30 and \>30-35 kg/m2, age, and gender with an equal number of subjects in each strata across groups. A subset of subjects will also wear a personal energy tracking device. Subjects will be instructed how to incorporate the shakes and supplements into their current diet and encouraged to incorporate fruits, vegetables, whole grains, and other healthy foods into their current meals and to exercise at least 30 minutes five days per week.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Between the ages of 18-65 years of age.
  • Body Mass Index (BMI) between 25-35
  • Willing to stop taking any nutritional supplements
Exclusion Criteria
  • Currently taking weight loss medication or supplements
  • Currently smoke
  • Taking any prescription medications
  • Experienced at least a 10 pound weight loss over the past 2 months.
  • History of serious heart problems (i.e. heart attack, angina, bypass surgery).
  • Diagnosed with diabetes (insulin or non-insulin dependent)
  • Known history of gastrointestinal diseases (i.e. Crohn's disease, chronic diarrhea, Inflammatory Bowel Disease)
  • Undergone surgical procedure for weight loss (i.e. gastroplasty, gastric by-pass, gastrectomy, stomach stapling, gastric banding, etc).
  • History of stroke or seizure activity
  • Medical conditions known to affect serum lipids
  • History of uncontrolled hypertension or with a current measured blood pressure with diastolic above 90 or systolic above 140 mm Hg
  • A total serum cholesterol above 240 mg/dL
  • Known HIV infection
  • Known history of depression and currently taking anti-depression medications
  • Treated for cancer in the last 5 years
  • Known allergies to supplements
  • Known history of eating disorder (i.e. bulimia, anorexia nervosa)
  • Known severe swallowing disorders
  • For females, known to be pregnant or breast-feeding or trying to become pregnant
  • Participating in another clinical (medical or nutritional) study or likely to be enrolled in another medical or nutritional protocol during this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Body weight changesSeveral measurements over 12 weeks
Secondary Outcome Measures
NameTimeMethod
Biophotonic scanner score, blood chemistry and metabolic profiles, adverse events, subjects' supplement preference, quality of life measurementsSeveral measurements over 12 weeks

Trial Locations

Locations (1)

Pharmanex

🇺🇸

Provo, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath